Athyrium Capital Management, LP

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 16, 2024), Athyrium Capital Management, LP reported 2 stock positions worth $18.7 million. Its top holding was Biora Therapeutics at 64.4% of the portfolio, followed by Puma Biotechnology (PBYI, 35.6%). Compared with Q4 2023, it reduced 1. The biggest sale was Puma Biotechnology (PBYI, shares −30%).

Most Recent 13F
Q3 2024
Location
New York, NY
CIK
0001728001
Portfolio Value
$18.7M (Q1 2024)
SEC Filing
0001123292-24-000137 ↗ filed May 16, 2024

Holdings Value

0$5.0M$10.0M$15.0M$20.0M Q1 2024: $18.7M $18.7M Q1 2024 Q2 2024: $11.3M Q2 2024 Q3 2024: $8.7M Q3 2024

Holdings 2 stocks · $18.7M
BIORA THERAPEUTICS INC 64.36% 10,929,762 $12.0M No change
PBYI Puma Biotechnology Inc. 35.64% 1,256,411 $6.7M Reduce -29.9%
Other holdings (1): bonds, preferreds, convertibles and warrants · $54.1M (not counted above)
SecurityClassShares / PrincipalValueChange
OMEROS CORP (OMER 5.25 02/15/26) NOTE 5.250% 2/1 · principal 72,979,000$54.1MNo change

Total filed on the 13F, all lines: $72.8M.

Portfolio Sells Q4 2023 → Q1 2024
PBYI Puma Biotechnology Inc. Reduce -29.9% 35.64% +1.18

Portfolio Buys Q4 2023 → Q1 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 2$8.7MBIORA THERAPEUTICS INC, PBYI
Q2 2024 2$11.3MBIORA THERAPEUTICS INC, PBYI
Q1 2024 2$18.7MBIORA THERAPEUTICS INC, PBYI